Drug Approval | April 12, 2025
FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Experts urge early detection & better access to care
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Subscribe To Our Newsletter & Stay Updated
